Chemical formula: C₁₄H₁₁NO₅ Molecular mass: 273.241 g/mol PubChem compound: 4659569
Tolcapone is an orally active, selective and reversible catechol-O-methyltransferase (COMT) inhibitor. Administered concomitantly with levodopa and an aromatic amino acid decarboxylase inhibitor (AADC-I), it leads to more stable plasma levels of levodopa by reducing metabolism of levodopa to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD). High levels of plasma 3-OMD have been associated with poor response to levodopa in Parkinson’s disease patients.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N04BX01 | Tolcapone | N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BX Other dopaminergic agents |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TASMAR Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Tolcapone is an active ingredient of these brands:
United States (US)Austria (AT)Brazil (BR)Croatia (HR)Cyprus (CY)Estonia (EE)France (FR)Ireland (IE)Italy (IT)Lithuania (LT)Netherlands (NL)New Zealand (NZ)Poland (PL)South Africa (ZA)Spain (ES)Turkey (TR)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
